ME03071B - Polipeptidi antitela koji antagonizuju cd40 - Google Patents

Polipeptidi antitela koji antagonizuju cd40

Info

Publication number: ME03071B
Authority: ME; Montenegro
Prior art keywords: antibody; antagonizing; polypeptides; antibody polypeptides; antagonizing antibody
Prior art date: 2011-04-21

Application number

MEP-2018-94A

Other languages

German (de)

English (en)

French (fr)

Inventor

Anish Suri

Steven Sheriff

Suzanne Suchard

Aaron Yamniuk

Stanley Krystek

James Tamura

James Bryson

Steven Grant

Philip Drew

Original Assignee

Bristol Myers Squibb Co

Domantis Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-21

Filing date

2012-04-20

Publication date

2019-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03071(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-04-20 Application filed by Bristol Myers Squibb Co, Domantis Ltd filed Critical Bristol Myers Squibb Co

2019-01-20 Publication of ME03071B publication Critical patent/ME03071B/me

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Hematology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Cardiology (AREA)

MEP-2018-94A 2011-04-21 2012-04-20 Polipeptidi antitela koji antagonizuju cd40 ME03071B (me)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161477904P	2011-04-21	2011-04-21
EP12717027.2A EP2699601B1 (en)	2011-04-21	2012-04-20	Antibody polypeptides that antagonize cd40
PCT/US2012/034519 WO2012145673A1 (en)	2011-04-21	2012-04-20	Antibody polypeptides that antagonize cd40

Publications (1)

Publication Number	Publication Date
ME03071B true ME03071B (me)	2019-01-20

Family

ID=46000407

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2018-94A ME03071B (me)	2011-04-21	2012-04-20	Polipeptidi antitela koji antagonizuju cd40

Country Status (35)

Country	Link
US (3)	US9475879B2 (me)
EP (2)	EP2699601B1 (me)
JP (2)	JP6114256B2 (me)
KR (2)	KR101734614B1 (me)
CN (2)	CN106977604A (me)
AR (1)	AR086360A1 (me)
AU (2)	AU2012245309C1 (me)
BR (1)	BR112013026828A2 (me)
CA (1)	CA2833743A1 (me)
CL (1)	CL2013003043A1 (me)
CO (1)	CO6801649A2 (me)
CY (1)	CY1120637T1 (me)
DK (1)	DK2699601T3 (me)
EA (1)	EA030851B1 (me)
ES (1)	ES2664619T3 (me)
HR (1)	HRP20180571T1 (me)
HU (1)	HUE038848T2 (me)
IL (1)	IL228720B (me)
LT (1)	LT2699601T (me)
MA (1)	MA35035B1 (me)
ME (1)	ME03071B (me)
MX (1)	MX354243B (me)
MY (1)	MY165090A (me)
NO (1)	NO2699601T3 (me)
PE (1)	PE20141188A1 (me)
PH (1)	PH12013502013B1 (me)
PL (1)	PL2699601T3 (me)
PT (1)	PT2699601T (me)
RS (1)	RS57087B1 (me)
SG (1)	SG194561A1 (me)
SI (1)	SI2699601T1 (me)
SM (1)	SMT201800228T1 (me)
TN (1)	TN2013000417A1 (me)
TW (2)	TWI598363B (me)
WO (1)	WO2012145673A1 (me)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT3556774T (pt)	2011-03-11	2024-02-29	Beth Israel Deaconess Medical Ct Inc	Anticorpos anti-cd40 e suas utilizações
CA2833743A1 (en) *	2011-04-21	2012-10-26	Bristol-Myers Squibb Company	Antibody polypeptides that antagonize cd40
US8778345B2 (en)	2011-04-29	2014-07-15	Apexigen, Inc.	Anti-CD40 antibodies
SMT202000091T1 (it)	2011-10-13	2020-05-08	Bristol Myers Squibb Co	Polipeptidi anticorpali che antagonizzano cd40l
KR102270618B1 (ko)	2012-10-30	2021-06-30	아펙시젠, 인코포레이티드	항-cd40 항체 및 사용 방법
US10435475B2 (en)	2014-03-07	2019-10-08	Bristol-Myers Squibb Company	Method of using antibody polypeptides that antagonize CD40 to treat IBD
JP6830437B2 (ja)	2014-12-10	2021-02-17	リージェンツオブザユニバーシティオブミネソタ	疾患を処置するための遺伝子改変された細胞、組織および臓器
US10689449B2 (en)	2015-01-20	2020-06-23	Igm Biosciences, Inc.	Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
MA41459A (fr)	2015-02-03	2017-12-12	Als Therapy Development Inst	Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
JP2018518474A (ja) *	2015-05-27	2018-07-12	ラ・ホヤ・バイオロジクス・インコーポレイテッド	グリピカン−３に対する抗体並びにがん診断及び治療におけるそれらの使用
PT3303395T (pt)	2015-05-29	2020-02-20	Abbvie Inc	Anticorpos anti-cd40 e usos dos mesmos
CN109069621B (zh)	2015-09-04	2022-09-06	普里玛托普医疗股份有限公司	人源化抗-cd40抗体及其用途
US20190086405A1 (en)	2016-03-16	2019-03-21	Bristol-Myers Squibb Company	Methods of diagnosing and treating lupus
WO2017220988A1 (en)	2016-06-20	2017-12-28	Kymab Limited	Multispecific antibodies for immuno-oncology
KR102019033B1 (ko)	2016-11-11	2019-09-06	다이노나(주)	Cd40에 특이적으로 결합하는 항체 및 그의 용도
MX2019007144A (es)	2016-12-19	2019-10-07	Glenmark Pharmaceuticals Sa	Nuevos agonistas de tnfr y sus usos.
SG11201908744PA (en) *	2017-03-23	2019-10-30	Univ Pennsylvania	Anti-c5a antibodies and uses thereof
KR102840867B1 (ko)	2017-05-24	2025-07-30	에이엘에스 테라피 디벨럽먼트 인스티튜트	치료용 항-cd40 리간드 항체
KR20200012907A (ko) *	2017-05-25	2020-02-05	브리스톨-마이어스 스큅 컴퍼니	변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체
AR111830A1 (es)	2017-05-25	2019-08-21	Bristol Myers Squibb Co	Anticuerpos monoclonales antagonistas contra cd40 y sus usos
CN110691795A (zh)	2017-05-30	2020-01-14	百时美施贵宝公司	包含抗-lag3抗体、pd-1途径抑制剂和免疫治疗剂组合的组合物
EP3632932A4 (en) *	2017-06-01	2021-08-18	Jiangsu Hengrui Medicine Co. Ltd.	ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THIS ANTIGEN AND ASSOCIATED MEDICAL USE
WO2019241730A2 (en)	2018-06-15	2019-12-19	Flagship Pioneering Innovations V, Inc.	Increasing immune activity through modulation of postcellular signaling factors
AR117091A1 (es)	2018-11-19	2021-07-07	Bristol Myers Squibb Co	Anticuerpos monoclonales antagonistas contra cd40 y sus usos
KR20210097750A (ko)	2018-11-30	2021-08-09	지앙수 헨그루이 메디슨 컴퍼니 리미티드	Cd40 항체 약학 조성물 및 이의 용도
TW202039558A (zh) *	2018-11-30	2020-11-01	大陸商江蘇恆瑞醫藥股份有限公司	抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途
WO2020159368A1 (en) *	2019-02-01	2020-08-06	Lava Therapeutics B.V.	Novel cd40-binding antibodies
EP3962493A2 (en)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V, Inc.	Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US20210032356A1 (en) *	2019-08-02	2021-02-04	Eastern Virginia Medical School	Method for treating seizures
US20230114107A1 (en)	2019-12-17	2023-04-13	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
IL293640A (en)	2019-12-20	2022-08-01	Amgen Inc	CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
KR20210095781A (ko)	2020-01-24	2021-08-03	주식회사 에이프릴바이오	항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11862306B1 (en)	2020-02-07	2024-01-02	Cvs Pharmacy, Inc.	Customer health activity based system for secure communication and presentation of health information
AU2021261003A1 (en) *	2020-04-23	2022-10-20	Alpha Beta Holdings, Llc	Compositions and methods for treating cancer
JP7523586B2 (ja)	2020-05-18	2024-07-26	ブリストル－マイヤーズスクイブカンパニー	改善された薬物動態特性を有する抗体変異体
CN116096906A (zh)	2020-06-29	2023-05-09	旗舰创业创新五公司	工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
WO2022212784A1 (en)	2021-03-31	2022-10-06	Flagship Pioneering Innovations V, Inc.	Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en)	2021-06-29	2024-01-18	Flagship Pioneering Innovations V, Inc.	Immune cells engineered to promote thanotransmission and uses thereof
US12234294B2 (en)	2021-11-05	2025-02-25	Kiniksa Pharmaceuticals, Gmbh	Pharmaceutical composition of a humanized anti-CD40 antibody
CN114149508B (zh) *	2021-11-25	2023-04-28	苏州普乐康医药科技有限公司	一种结合cd40l的融合蛋白及其应用
US20250179170A1 (en)	2022-03-08	2025-06-05	Alentis Therapeutics Ag	Use of anti-claudin-1 antibodies to increase t cell availability
CN116023495B (zh) *	2022-09-05	2023-10-03	上海百英生物科技股份有限公司	一种抗cd40纳米抗体及其制备方法与应用
EP4598946A1 (en)	2022-10-05	2025-08-13	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en)	2023-01-09	2024-08-15	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
KR20250057233A (ko)	2023-10-20	2025-04-29	한상진	이동식 무선 자동 제습기
WO2025129007A1 (en) *	2023-12-15	2025-06-19	Werewool Inc.	Soy alginate fibers
US20250277048A1 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182368A (en)	1986-06-13	1993-01-26	Ledbetter Jeffrey A	Ligands and methods for augmenting B-cell proliferation
US5247069A (en)	1986-06-13	1993-09-21	Oncogen	Ligands and methods for augmenting B-cell proliferation
US5506126A (en)	1988-02-25	1996-04-09	The General Hospital Corporation	Rapid immunoselection cloning method
CA2089229C (en)	1992-02-14	2010-04-13	Alejandro A. Aruffo	Cd40cr receptor and ligands therefor
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
AU680102B2 (en)	1993-12-23	1997-07-17	Immunex Corporation	Method of preventing or treating disease characterized by neoplastic cells expressing CD40
JP4751493B2 (ja)	1996-03-20	2011-08-17	ブリストル−マイヤーズスクイッブカンパニー	Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
US6051228A (en)	1998-02-19	2000-04-18	Bristol-Myers Squibb Co.	Antibodies against human CD40
JP4202127B2 (ja) *	2000-10-02	2008-12-24	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
ATE476448T1 (de)	2003-11-04	2010-08-15	Novartis Vaccines & Diagnostic	Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat- abstossung
US8277810B2 (en)	2003-11-04	2012-10-02	Novartis Vaccines & Diagnostics, Inc.	Antagonist anti-CD40 antibodies
BRPI0417266B8 (pt)	2003-12-25	2021-05-25	Kyowa Hakko Kirin Co Ltd	anticorpo monoclonal, seu uso e composição farmacêutica
PT1737962E (pt)	2004-03-24	2010-12-03	Domantis Ltd	Sequência líder universal gas1
MXPA06012430A (es)	2004-04-27	2007-04-19	Novartis Vaccines & Diagnostic	Anticuerpos monoclonales antagonistas anti-cd40 y metodos para su uso.
ZA200702427B (en)	2004-09-17	2008-12-31	Domantis Ltd	Compositions monovalent for CD40L binding and methods of use
US7563443B2 (en) *	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
AR053579A1 (es)	2005-04-15	2007-05-09	Genentech Inc	Tratamiento de la enfermedad inflamatoria intestinal (eii)
US20070014720A1 (en)	2005-06-02	2007-01-18	Gadi Gazit-Bornstein	Antibodies directed to CD20 and uses thereof
ZA200804868B (en) *	2005-12-16	2009-10-28	Genentech Inc	Anti-OX40L antibodies and methods using same
AU2007209202A1 (en)	2006-01-24	2007-08-02	Domantis Limited	Ligands that bind IL-4 and/or IL-13
KR101317235B1 (ko)	2006-04-21	2013-10-15	조마 테크놀로지 리미티드	길항제 항-ｃｄ40 항체 제약 조성물
EP1854810A1 (en)	2006-05-09	2007-11-14	PanGenetics B.V.	Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
GB0724331D0 (en)	2007-12-13	2008-01-23	Domantis Ltd	Compositions for pulmonary delivery
MX2010011808A (es) *	2008-04-30	2011-03-04	Immunogen Inc	Conjugados potentes y enlazadores hidrofilicos.
CN104398471A (zh) *	2008-11-28	2015-03-11	Abbvie公司	稳定的抗体组合物和用于稳定其的方法
HUE038788T2 (hu)	2010-03-31	2018-11-28	Boehringer Ingelheim Int	Anti-CD40 antitestek
AR083847A1 (es)	2010-11-15	2013-03-27	Novartis Ag	Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
CA2833743A1 (en)	2011-04-21	2012-10-26	Bristol-Myers Squibb Company	Antibody polypeptides that antagonize cd40

2012
- 2012-04-20 CA CA2833743A patent/CA2833743A1/en not_active Abandoned
- 2012-04-20 KR KR1020137030492A patent/KR101734614B1/ko not_active Expired - Fee Related
- 2012-04-20 DK DK12717027.2T patent/DK2699601T3/en active
- 2012-04-20 ME MEP-2018-94A patent/ME03071B/me unknown
- 2012-04-20 PE PE2013002381A patent/PE20141188A1/es active IP Right Grant
- 2012-04-20 RS RS20180346A patent/RS57087B1/sr unknown
- 2012-04-20 SI SI201231203T patent/SI2699601T1/en unknown
- 2012-04-20 CN CN201710070840.9A patent/CN106977604A/zh active Pending
- 2012-04-20 SM SM20180228T patent/SMT201800228T1/it unknown
- 2012-04-20 WO PCT/US2012/034519 patent/WO2012145673A1/en not_active Ceased
- 2012-04-20 US US14/112,049 patent/US9475879B2/en active Active
- 2012-04-20 ES ES12717027.2T patent/ES2664619T3/es active Active
- 2012-04-20 CN CN201280030683.4A patent/CN103842382B/zh not_active Expired - Fee Related
- 2012-04-20 PT PT127170272T patent/PT2699601T/pt unknown
- 2012-04-20 AR ARP120101368A patent/AR086360A1/es unknown
- 2012-04-20 MY MYPI2013003839A patent/MY165090A/en unknown
- 2012-04-20 MA MA36322A patent/MA35035B1/fr unknown
- 2012-04-20 MX MX2013011966A patent/MX354243B/es active IP Right Grant
- 2012-04-20 KR KR1020177011260A patent/KR101905346B1/ko not_active Expired - Fee Related
- 2012-04-20 EP EP12717027.2A patent/EP2699601B1/en active Active
- 2012-04-20 SG SG2013078183A patent/SG194561A1/en unknown
- 2012-04-20 HU HUE12717027A patent/HUE038848T2/hu unknown
- 2012-04-20 LT LTEP12717027.2T patent/LT2699601T/lt unknown
- 2012-04-20 HR HRP20180571TT patent/HRP20180571T1/hr unknown
- 2012-04-20 TW TW105121984A patent/TWI598363B/zh not_active IP Right Cessation
- 2012-04-20 BR BR112013026828A patent/BR112013026828A2/pt not_active Application Discontinuation
- 2012-04-20 EA EA201391564A patent/EA030851B1/ru not_active IP Right Cessation
- 2012-04-20 JP JP2014506589A patent/JP6114256B2/ja not_active Expired - Fee Related
- 2012-04-20 EP EP18151812.7A patent/EP3372616A1/en not_active Withdrawn
- 2012-04-20 TW TW101114258A patent/TW201245225A/zh unknown
- 2012-04-20 AU AU2012245309A patent/AU2012245309C1/en not_active Ceased
- 2012-04-20 NO NO12717027A patent/NO2699601T3/no unknown
- 2012-04-20 PL PL12717027T patent/PL2699601T3/pl unknown
2013
- 2013-09-27 PH PH12013502013A patent/PH12013502013B1/en unknown
- 2013-10-03 IL IL228720A patent/IL228720B/en active IP Right Grant
- 2013-10-11 TN TNP2013000417A patent/TN2013000417A1/fr unknown
- 2013-10-21 CL CL2013003043A patent/CL2013003043A1/es unknown
- 2013-11-05 CO CO13261140A patent/CO6801649A2/es active IP Right Grant
2016
- 2016-04-27 AU AU2016202672A patent/AU2016202672B2/en not_active Ceased
- 2016-09-08 US US15/259,828 patent/US10544228B2/en active Active
2017
- 2017-01-05 JP JP2017000493A patent/JP2017099391A/ja active Pending
2018
- 2018-04-16 CY CY181100398T patent/CY1120637T1/el unknown
2019
- 2019-12-20 US US16/723,047 patent/US11136406B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
RS57087B1 (sr)	2018-06-29
EP2699601B1 (en)	2018-01-17
SMT201800228T1 (it)	2018-07-17
CY1120637T1 (el)	2019-12-11
TN2013000417A1 (en)	2015-03-30
HUE038848T2 (hu)	2018-11-28
EP2699601A1 (en)	2014-02-26
US11136406B2 (en)	2021-10-05
BR112013026828A2 (pt)	2016-11-29
US20140099317A1 (en)	2014-04-10
AU2012245309C1 (en)	2016-07-21
CO6801649A2 (es)	2013-11-29
DK2699601T3 (en)	2018-04-23
JP2017099391A (ja)	2017-06-08
LT2699601T (lt)	2018-03-26
CN103842382A (zh)	2014-06-04
JP2014513953A (ja)	2014-06-19
PH12013502013B1 (en)	2018-11-28
CA2833743A1 (en)	2012-10-26
EA201391564A1 (ru)	2014-02-28
KR101905346B1 (ko)	2018-10-05
AR086360A1 (es)	2013-12-11
US20200199244A1 (en)	2020-06-25
TWI598363B (zh)	2017-09-11
SG194561A1 (en)	2013-12-30
AU2016202672A1 (en)	2016-05-26
SI2699601T1 (en)	2018-04-30
TW201712038A (zh)	2017-04-01
US9475879B2 (en)	2016-10-25
PL2699601T3 (pl)	2018-05-30
TW201245225A (en)	2012-11-16
PT2699601T (pt)	2018-04-05
ES2664619T3 (es)	2018-04-20
AU2016202672B2 (en)	2017-07-20
HRP20180571T1 (hr)	2018-05-18
NO2699601T3 (me)	2018-06-16
CN103842382B (zh)	2017-03-15
JP6114256B2 (ja)	2017-04-12
MX354243B (es)	2018-02-20
EP3372616A1 (en)	2018-09-12
AU2012245309B2 (en)	2016-02-04
NZ618025A (en)	2015-10-30
EA030851B1 (ru)	2018-10-31
MY165090A (en)	2018-02-28
US10544228B2 (en)	2020-01-28
AU2012245309A1 (en)	2013-12-12
IL228720A0 (en)	2013-12-31
KR20140009505A (ko)	2014-01-22
IL228720B (en)	2018-12-31
CL2013003043A1 (es)	2014-06-20
MX2013011966A (es)	2014-02-11
PE20141188A1 (es)	2014-09-22
MA35035B1 (fr)	2014-04-03
KR20170049628A (ko)	2017-05-10
US20170015754A1 (en)	2017-01-19
CN106977604A (zh)	2017-07-25
KR101734614B1 (ko)	2017-05-12
WO2012145673A1 (en)	2012-10-26

Publication	Publication Date	Title
ME03071B (me)	2019-01-20	Polipeptidi antitela koji antagonizuju cd40
HUS2300021I1 (hu)	2023-07-28	Anti-IL-36R antitestek
DK2766395T3 (da)	2020-02-24	Antistofpolypeptider, der antagoniserer cd40l
PL3415531T3 (pl)	2024-02-26	Białka wiążące antygen
DK2768524T3 (da)	2022-07-04	PD-L1-baseret immunterapi
BR112014004902A2 (pt)	2017-07-04	peptídeos
EP2728002A4 (en)	2015-03-25	HETERODIMIZED POLYPEPTIDE
HUE040326T2 (hu)	2019-03-28	Mutáns interleukon-2 polipeptidek
CO6811812A2 (es)	2013-12-16	Anticuerpo anti-b7-h3
HUE036663T2 (hu)	2018-07-30	Készítmény anti-alfa4béta7 antitesthez
HUE036664T2 (hu)	2018-07-30	Készítmény anti-alfa4béta7 antitesthez
CR20140127A (es)	2014-08-20	Anticuerpo anti-abtcr
FI20116212L (fi)	2013-06-02	Polypeptidi
LT2742068T (lt)	2019-07-10	Nauji antikūnai prieš fosforilcholiną
EP2703307A4 (en)	2014-11-12	BOTTLE
CO6841994A2 (es)	2014-01-20	Anticuerpos
EP2738107A4 (en)	2015-03-04	BOTTLE
BR112013019773A2 (pt)	2017-07-11	polipeptídeos antigênicos gly1.
DK2718316T3 (da)	2020-02-17	Polypeptider
ES1075991Y (es)	2012-04-24	Arrancahierbas
ITPN20110007U1 (it)	2011-06-23	Contenitore multifunzione
UA21768S (uk)	2011-04-26	Пляшка
UA22432S (uk)	2011-11-10	Пляшка
UA21953S (uk)	2011-06-10	Пляшка
UA22709S (uk)	2012-02-10	Пляшка